Purdue Researchers Develop Next-Generation Automated Platform to Accelerate Drug Discovery – Purdue Institute for Cancer Research
oncodaily - Purdue Institute for Cancer Research shared a post on LinkedIn: “Purdue researchers, including Nicolás Morato and R. Graham Cooks, have developed a next-generation platform that integrates chemical synthesis, biological testing, […]
AI Summary: Purdue researchers unveiled an automated mass‑spectrometry platform that compresses key steps of small‑molecule drug discovery into a matter of hours, promising faster lead identification and screening. The system couples high‑throughput chemistry with rapid readouts to accelerate iteration cycles, potentially shrinking timelines and costs for early oncology drug development — welcome news for impatient scientists.
Related Stories
Dendritic cells build tumour immune hubs sustaining anti-tumour responses / 16 days
Engineered CAR‑T cells secreting VEGF‑neutralizing scFvs boost solid‑tumor activity / 4 months
Phase 1 trial shows cevostamab activity in relapsed multiple myeloma / 10 days
EMERALD‑3 tests tremelimumab/durvalumab combos for embolisation‑eligible HCC / 4 wks
Phages repurpose vaccine immunity to attack cancer cells / 5 wks
Long‑term Botensilimab+Balstilimab data show durable responses in MSS CRC / 5 wks
Some tumors kill neighboring healthy cells to fuel growth / 1 month
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try CDC, Price Transparency, Adolescent Health, Mergers and Acquisitions and look for the RSS link.
StackHealth Time Machine